DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

WKN: 578560 ISIN: DE0005785604 Fresenius SE & Co. KGaA (St.)

42,01 EUR
0,64 EUR 1,55 %
14.12.2018 - 17:35
06.12.2018 22:30:25

DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

06-Dec-2018 / 22:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

Current Group expectations for FY 2019
Based on the current status of the Group's budget process and its FY 2018 guidance, Fresenius expects mid-single digit organic sales growth for FY 2019. Group net income1,2, however, is expected to be broadly stable over FY 2018. Fresenius continues to seek both sales growth and efficiency improvement initiatives in order to enhance these expectations.

Current Group expectations
Given its current expectations for FY 2018 and FY 2019, Fresenius now believes its ambitious Group targets for 2020 will not be met.

From 2020 onwards, Fresenius now expects sustainable organic Group sales growth in the mid-single digits. Group net income2,3 is expected to grow organically slightly faster than sales. Upon Fresenius Kabi's biosimilars business breaking even, Fresenius expects an acceleration of Group earnings growth. Unlike previous mid-term targets, these expectations exclude the effect of small- to medium-sized acquisitions.

Fresenius will announce detailed FY 2019 financial guidance and mid-term targets with the release of its FY 2018 results on February 20, 2019.

----------------------------------------
1 In constant currency, before special items and effects of IFRS 16, incl. expenses for the further development of the biosimilars business, H1/18 adjusted for divestitures of Care Coordination activities. 2019 including NxStage operating results.
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
3 Before special items

----------------------------------------

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.

(Financial statements according to IFRS)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., December 6, 2018

Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com

End of note


06-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange

 
End of Announcement DGAP News Service

755395  06-Dec-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=755395&application_name=news&site_id=smarthouse

Aktien in diesem Artikel

Fresenius SE & Co. KGaA (St.) 42,01 1,55% Fresenius SE & Co. KGaA (St.)

Nachrichten zu Fresenius SE & Co. KGaA (St.)

  • Relevant
  • Alle
  • vom Unternehmen

Aktienempfehlungen zu Fresenius SE & Co. KGaA (St.)

  • Alle
  • Buy
  • Hold
  • Sell
13.12.18 Fresenius Neutral Credit Suisse Group
13.12.18 Fresenius kaufen Norddeutsche Landesbank (Nord/LB)
12.12.18 Fresenius buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.12.18 Fresenius buy Warburg Research
10.12.18 Fresenius Neutral Oddo BHF
mehr Aktienempfehlungen

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten
pagehit